Hyperforin Analog Synthesis via Modular Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing hyperforin are inefficient, with only a single total synthesis achieved in 51 steps and 0.05% yield, and existing approaches are not amenable to producing hyperforin analogs for biological evaluation.
Innovation Solution
A novel 11-step enantioselective approach to hyperforin synthesis, enabling the production of hyperforin analogs for pharmaceutical compositions, which can treat depression and other conditions such as inflammatory skin conditions, diabetes, asthma, and ischemic brain damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If the traditional Shibasaki synthesis method is used, then hyperforin can be synthesized with enantioselectivity, but the synthesis requires 51 steps with only 0.05% overall yield
Solution Approach 1:
The synthesis is divided into modular segments: (a) preparation of chiral building blocks with defined stereochemistry, (b) construction of the bicyclic core through key cyclization reactions, and (c) installation of polyprenyl side chains. This segmentation allows each module to be optimized independently, reducing overall complexity and improving yield while maintaining enantioselectivity.
Solution Approach 2:
Chiral building blocks and key intermediates are prepared in advance with predetermined stereochemistry. The enantioselective steps are performed early in the synthesis sequence, establishing the chiral framework before subsequent transformations. This preliminary establishment of stereochemistry eliminates the need for later chiral resolution steps, improving overall yield.
2Manufacturing precision
If the Shibasaki synthesis method is used, then hyperforin enantiomers can be obtained, but the method is not easily amenable to synthesis of hyperforin analogs
Solution Approach 1:
The synthetic methodology employs universal chiral building blocks and reaction conditions that can be applied to synthesize not only hyperforin but also a wide range of analogs with different side chain substitutions. The modular design allows the same core synthesis protocol to be adapted for producing enantiomers of various hyperforin derivatives by simply changing the starting materials or side chain installation steps.
Solution Approach 2:
The synthesis allows for local modification of specific regions of the molecule while maintaining the chiral core. Different polyprenyl side chains can be installed at specific positions on the bicyclic core through selective alkylation reactions, enabling the production of analogs with tailored properties while preserving the enantioselective synthesis advantage.
3Reliability
If hyperforin is used as a therapeutic lead, then TRPC6 activation and antidepressant effects are achieved, but water solubility is poor
Solution Approach 1:
The patent modifies the physicochemical parameters of hyperforin by introducing polar functional groups or modifying the side chain composition to increase water solubility. These parameter changes are made while preserving the core bicyclic structure and TRPC6-binding pharmacophore, thereby maintaining antidepressant efficacy while improving solubility characteristics for better pharmacokinetic properties.
4Reliability
If hyperforin is used as a therapeutic lead, then antidepressant activity is achieved, but PXR activation causes upregulation of CYPs and resultant metabolism of other drugs
Solution Approach 1:
The patent extracts or removes the PXR-binding moiety from the hyperforin structure while retaining the TRPC6-activating pharmacophore. By eliminating the portion of the molecule responsible for PXR activation and subsequent CYP upregulation, the analogs maintain antidepressant efficacy through TRPC6 activation without causing harmful drug-drug interactions via the PXR pathway.
Data Source
AI summary
The present invention provides a novel 11-step enantioselective approach to the natural product hyperforin, which enables access to a wide variety of hyperforin analogs. The present invention also provides pharmaceutical compositions comprising inventive hyperforin analogs. Hyperforin analogs synthesized using the present synthetic method are envisioned useful in the treatment of various conditions, including, but not limited to, depression and conditions characterized by depression, inflammatory skin conditions, diabetes, asthma, chronic obstructive pulmonary disease (COPD), kidney disorders, and ischemic brain damage.